Department of Pharmacy, Pharmaceutical Outcomes Research and Policy Program, Institute for Public Health Genetics, University of Washington, Seattle, Washington, USA.
Genet Med. 2013 Jan;15(1):14-24. doi: 10.1038/gim.2012.106. Epub 2012 Sep 6.
To provide an update on recent revisions to Evaluation of Genomic Applications in Practice and Prevention (EGAPP) methods designed to improve efficiency, and an assessment of the implications of whole genome sequencing for evidence-based recommendation development. Improvements to the EGAPP approach include automated searches for horizon scanning, a quantitative ranking process for topic prioritization, and the development of a staged evidence review and evaluation process. The staged process entails (i) triaging tests with minimal evidence of clinical validity, (ii) using and updating existing reviews, (iii) evaluating clinical validity prior to analytic validity or clinical utility, (iv) using decision modeling to assess potential clinical utility when direct evidence is not available. EGAPP experience to date suggests the following approaches will be critical for the development of evidence based recommendations in the whole genome sequencing era: (i) use of triage approaches and frameworks to improve efficiency, (ii) development of evidence thresholds that consider the value of further research, (iii) incorporation of patient preferences, and (iv) engagement of diverse stakeholders. The rapid advances in genomics present a significant challenge to traditional evidence based medicine, but also an opportunity for innovative approaches to recommendation development.
提供最近修订的实践和预防中的基因组应用评估 (EGAPP) 方法的更新,这些方法旨在提高效率,并评估全基因组测序对循证推荐制定的影响。EGAPP 方法的改进包括自动化 horizon scanning 搜索、主题优先级的定量排名过程,以及分阶段的证据审查和评估过程。分阶段过程包括 (i) 对临床有效性证据最少的测试进行分类,(ii) 使用和更新现有审查,(iii) 在分析有效性或临床实用性之前评估临床有效性,(iv) 在没有直接证据时使用决策建模评估潜在的临床实用性。迄今为止,EGAPP 的经验表明,以下方法对于全基因组测序时代循证推荐的制定将至关重要:(i) 使用分类方法和框架来提高效率,(ii) 制定考虑进一步研究价值的证据阈值,(iii) 纳入患者偏好,以及 (iv) 吸引不同的利益相关者。基因组学的快速发展对传统的循证医学提出了重大挑战,但也为推荐制定提供了创新方法的机会。